Education
About Us
Working with TipRanks
Follow Us
Evommune, Inc. (EVMN)
NYSE:EVMN
EVMN Stock Chart & Stats
$31.10
--
Market closed
$31.10
--
Day’s Range― - ―
52-Week Range$13.89 - $33.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)923.04K
Market Cap
$819.63M
Enterprise Value$565.60M
Total Cash (Recent Filing)$76.06M
Total Debt (Recent Filing)$257.77M
Price to Earnings (P/E)―
Beta-2.39
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding31,524,094
10 Day Avg. Volume407,170
30 Day Avg. Volume923,043
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)-4.22
Price to Sales (P/S)86.92
P/FCF Ratio-10.44
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue43.51
Enterprise Value/Gross Profit47.38
Enterprise Value/Ebitda-9.72
Forecast
1Y Price Target
$51.20Price Target Upside64.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.63
Revenue Forecast (FY)$9.62M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue GrowthSustained ~80–82% gross margins alongside revenue growth indicate scalable unit economics and durable product-level profitability. This margin cushion can fund incremental R&D or commercialization as revenue scales, improving operating leverage and long-term viability if growth continues.
Focused Therapeutic StrategyA concentrated focus on immune-mediated inflammatory diseases targets a large, persistent clinical market with ongoing unmet needs. This strategic clarity supports efficient R&D prioritization, clearer development pathways, and potential long-term commercial opportunities if clinical programs advance successfully.
Cash Outflow Aligns With Reported LossesFree cash flow tracking net loss suggests operating cash burn largely reflects ongoing business activity rather than volatile noncash charges. That alignment improves predictability of financing needs and supports more reliable runway and capital planning over the medium term.
Bears Say
Worsening Negative Equity & Rising DebtDeepening negative equity and sharply higher debt materially erode financial flexibility. Elevated leverage increases refinancing, covenant and dilution risks, constrains strategic choices, and raises the likelihood that future capital raises will be required under unfavorable terms.
Accelerating Cash BurnA near-doubling of operating cash outflows shortens runway and forces prioritization of programs or near-term external financing. Accelerating burn elevates execution risk for development timelines and increases the probability of dilutive capital raises if operational improvements or new funding aren't secured.
Deepening Operating & Net LossesMaterially larger operating and net losses show the fixed cost base far exceeds current revenue, limiting the company's ability to self-fund development. Persistent negative margins make long-term progress dependent on external capital or major cost restructuring, increasing strategic risk.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $13.88 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $819.63M.
When is Evommune, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evommune, Inc.’s earnings last quarter?
Evommune, Inc. released its earnings results on Dec 11, 2025. The company reported -$8.07 earnings per share for the quarter, missing the consensus estimate of -$6.081 by -$1.989.
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 31,524,094 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Evommune, Inc. reported an EPS of -$8.07 in its last earnings report, missing expectations of -$6.081. Following the earnings report the stock price went down -8.532%.
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Company Description
Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$51.20
▲(64.63% Upside)